ROS1 NSCLC Test sale cost 2100 AED
ALK EML4 NSCLC Test sale cost 2550 AED ALK EML4 NSCLC Test Cost 2,830 د.إ Original price was: 2,830 د.إ.2,550 د.إCurrent price is: 2,550 د.إ.
Ganglioside GQ1B Antibody IgG Test sale cost 2500 AED Ganglioside GQ1B Antibody IgG Test Cost 2,780 د.إ Original price was: 2,780 د.إ.2,500 د.إCurrent price is: 2,500 د.إ.
Sale!

ROS1 NSCLC Test Cost

Original price was: 2,800 د.إ.Current price is: 2,100 د.إ.

-25%

The ROS1 NSCLC Test is a specialized diagnostic assessment designed to detect rearrangements in the ROS1 gene, which are critical for guiding the treatment of non-small cell lung cancer (NSCLC). This molecular testing is pivotal for identifying patients who are likely to benefit from targeted therapy options that specifically inhibit the ROS1 protein. By pinpointing this genetic alteration, healthcare providers can tailor treatment plans that are more effective and potentially have fewer side effects compared to conventional chemotherapy.

Performed at DNA Labs UAE, a facility known for its advanced diagnostic technologies and expert staff, the test ensures high accuracy and reliability. The cost of the ROS1 NSCLC Test is 2100 AED, an investment in precision medicine that can significantly impact the treatment outcomes for patients with NSCLC. This test represents a crucial step in the journey towards personalized cancer therapy, offering hope for improved survival rates and quality of life for patients.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

ROS 1 NSCLC Test – Cost, Symptoms, Diagnosis | DNA Labs UAE

Test Name: ROS 1 NSCLC Test

Components: Paraffin embedded tissue blocks

Price: 2100.0 AED

Sample Condition: Tumor tissue

Report Delivery: 7-8 days

Method: FISH

Test Type: Genetics

Doctor: Oncology

Test Department:

Pre Test Information: ROS 1 (NSCLC) can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details

ROS1 (ROS proto-oncogene 1) is a gene that encodes for a receptor tyrosine kinase protein involved in cell signaling pathways. It is commonly associated with a type of non-small cell lung cancer (NSCLC) known as ROS1-positive NSCLC.

ROS1-positive NSCLC is a subtype of NSCLC characterized by a rearrangement or fusion of the ROS1 gene with another gene, resulting in the overexpression and activation of the ROS1 protein. This genetic alteration is found in approximately 1-2% of NSCLC cases.

ROS1 inhibitors, such as crizotinib, ceritinib, and entrectinib, have been developed and approved for the treatment of ROS1-positive NSCLC. These targeted therapies specifically block the activity of the ROS1 protein, inhibiting the growth and spread of cancer cells.

Patients with ROS1-positive NSCLC typically have a better response to ROS1 inhibitors compared to standard chemotherapy. However, resistance to these targeted therapies can develop over time, leading to disease progression. Ongoing research is focused on understanding the mechanisms of resistance and developing new treatment strategies for ROS1-positive NSCLC.

Test Name ROS 1 NSCLC Test
Components Paraffin embedded tissue blocks
Price 2100.0 AED
Sample Condition Tumor tissue
Report Delivery 7-8 days
Method FISH
Test type Genetics
Doctor Oncology
Test Department:
Pre Test Information ROS 1 (NSCLC) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

ROS1 (ROS proto-oncogene 1) is a gene that encodes for a receptor tyrosine kinase protein involved in cell signaling pathways. It is commonly associated with a type of non-small cell lung cancer (NSCLC) known as ROS1-positive NSCLC.

ROS1-positive NSCLC is a subtype of NSCLC characterized by a rearrangement or fusion of the ROS1 gene with another gene, resulting in the overexpression and activation of the ROS1 protein. This genetic alteration is found in approximately 1-2% of NSCLC cases.

ROS1 inhibitors, such as crizotinib, ceritinib, and entrectinib, have been developed and approved for the treatment of ROS1-positive NSCLC. These targeted therapies specifically block the activity of the ROS1 protein, inhibiting the growth and spread of cancer cells.

Patients with ROS1-positive NSCLC typically have a better response to ROS1 inhibitors compared to standard chemotherapy. However, resistance to these targeted therapies can develop over time, leading to disease progression. Ongoing research is focused on understanding the mechanisms of resistance and developing new treatment strategies for ROS1-positive NSCLC.

SKU: TEST-4879